Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 24, 2019 12:00 ET | Source: Deinove

L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019

L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019 Le Major Steven Zumbrun (USAMRIID1, Département de la Défense des Etats-Unis) a présenté la...
June 24, 2019 12:00 ET | Source: Deinove

DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019

DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019 Major Steven Zumbrun (USAMRIID1, U.S. Department of Defense) presented data on the in vitro assessment of...
March 24, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

PHILADELPHIA, March 24, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European subsidiary, "Hemispherx Biopharma Europe...
March 23, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus

PHILADELPHIA, March 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") will present integrated findings of new studies of Ampligen®...
February 12, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses

Ampligen® May Be an Important Candidate for EBOV Testing in West Africa PHILADELPHIA, Feb. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or...
February 02, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study

PHILADELPHIA, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the results of a new efficacy study of Ampligen® in a...
January 26, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments

PHILADELPHIA, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that in a new publication in the journal mBio, scientists at...
December 09, 2014 09:51 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research

PHILADELPHIA, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that it has received a new research report (dated December 5,...
November 03, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Collaborate on Alferon(R) and Ampligen(R) Against the Ebola Virus

PHILADELPHIA, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has been informed by USAMRIID scientists that they have in-vitro data...